MENU
BIB
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

BIB stock forecast, quote, news & analysis

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®... Show more

Category: #Trading
Interact to see
Advertisement
A.I.Advisor
published price charts
BIB
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for BIB with price predictions
Oct 21, 2026

BIB in +7.12% Uptrend, advancing for three consecutive days on October 21, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BIB advanced for three days, in 291 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on BIB as a result. In 79 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for BIB just turned positive on October 20, 2026. Looking at past instances where BIB's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.

BIB moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

BIB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for BIB crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for BIB entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares Ultra Nasdaq Biotechnology (BIB) ETF is 8.64B. The market cap for tickers in the group ranges from 37.07M to 236.98B. AMGN holds the highest valuation in this group at 236.98B. The lowest valued company is EYPT at 37.07M.

High and low price notable news

The average weekly price growth across all stocks in the ProShares Ultra Nasdaq Biotechnology (BIB) ETF was 110%. For the same ETF, the average monthly price growth was 161%, and the average quarterly price growth was 396%. SLN experienced the highest price growth at 119%, while EYPT experienced the biggest fall at -86%.

Volume

The average weekly volume growth across all stocks in the ProShares Ultra Nasdaq Biotechnology (BIB) ETF was -8%. For the same stocks of the ETF, the average monthly volume growth was 12% and the average quarterly volume growth was -25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 47
Price Growth Rating: 55
SMR Rating: 86
Profit Risk Rating: 83
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
BIB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com
BIB in +7.12% Uptrend, advancing for three consecutive days on October 21, 2026